Jun/Jul Issue On Sale Now!
Quick and Easy Huevos Rancheros
Today's Top Diabetes Stories...
The U.S. Food and Drug Administration has learned that some stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc. have reappeared and are being sold in the U.S. market. Three lots or a total of 129,000 vials of this product were stolen in all. These stolen insulin vials may not have been stored and handled properly and may be dangerous for patients to use.
The FDA has received one report of a patient who suffered an adverse event due to poor control of glucose levels after using a vial from one of these three lots.
The agency is advising patients who use Levemir insulin to: 1. Check your personal supply of insulin to determine if you have Levemir insulin from one of the following lots: XZF0036, XZF0037, and XZF0038. Patients can locate the lot number on the side of the box of insulin and also on the side of the vial. Read more...
1 comment -
Jun 22, 2009 -
One of the fondest hopes of people with type 1 diabetes has long been for the creation of an artificial pancreas, a reliable combination of automated glucose monitoring and insulin delivery that could serve in place of a defunct pancreas.
Apparently the hoped-for day may be here: Researchers from the University of California and Sansum Diabetes Research Institute, in Santa Barbara, California, have demonstrated an automated artificial pancreas system that they say is reliable enough to free type 1 patients from having to manually control their insulin pumps.
The scientists introduced the system, which combines the OmniPod insulin delivery system and the DexCom STS7 continuous glucose monitor with a software component, to the 69th Scientific Sessions of the American Diabetes Association in New Orleans earlier this month. (OmniPod is manufactured by Insulet Corporation; DexCom is manufactured by DexCom, Inc.) Read more...
16 comments -
Jun 24, 2009 -
A surgeon who has been at the forefront of exploring bariatric surgery as a potentially curative treatment for type 2 diabetes is calling for it to be made accessible to more people.
Francesco A. Rubino, MD, is the chief of gastrointestinal metabolic surgery at Weill Cornell Medical College and head of the Diabetes Surgery Center at New York Presbyterian/Weill Cornell Medical College.
During a seminar at the recent 69th Scientific Sessions of the American Diabetes Association, he told attendees that the criteria for determining who can undergo the surgery should be changed to allow more overweight people to use it. Read more...
5 comments -
Jun 23, 2009 -
